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Abstract: Tapping into the ability of engineered mesenchymal stem cells (MSCs) to mobilise into the
tumour has expanded the scope of cancer treatment. Engineered MSCs expressing tumour necrosis
factor (TNF)-related apoptosis inducing ligand (MSC-TRAIL) could serve as a platform for an efficient
and targeted form of therapy. However, the presence of cancer stem cells (CSCs) that are resistant
to TRAIL and apoptosis may represent a challenge for effective treatment. Nonetheless, with the
discovery of small molecular inhibitors that could target CSCs and tumour signalling pathways,
a higher efficacy of MSC-TRAIL mediated tumour inhibition can be achieved. This might pave
the way for a more effective form of combined therapy, which leads to a better treatment outcome.
In this review, we first discuss the tumour-homing capacity of MSCs, its effect in tumour tropism,
the different approach behind genetically-engineered MSCs, and the efficacy and safety of each agent
delivered by these MSCs. Then, we focus on how sensitisation of CSCs and tumours using small
molecular inhibitors can increase the effect of these cells to either TRAIL or MSC-TRAIL mediated
inhibition. In the conclusion, we address a few questions and safety concerns regarding the utilization
of engineered MSCs for future treatment in patients.
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1. Introduction
The GLOBOCAN 2012 report published by the World Health Organization estimates that there
were about 14.1 million new cancer cases, 8.2 million cancer deaths, and 32.6 million people living
with cancer in 2012 [1]. It was predicted that in 2025, there would be a sharp increase in new cancer
cases, of up to 19.3 million total cases, because of the ageing population [1]. Despite considerable
advances in our knowledge and experience in the treatment of cancer, our capacity to effectively fight
and treat the disease is still limited [2]. Current treatments only manage to reduce the burden of
the primary lesion but are rarely effective in the complete eradication of tumour cells, which in turn
leads to relapse and even fatality [3]. This is due to the existence of chemotherapy-resistant cancer
stem cells (CSCs) that can repopulate the tumour after the initial chemotherapy [4]. This warrants
the need for a more efficient and innovative approach that can enhance treatment efficacy in cancer
patients. The idea of using mesenchymal stem cells (MSCs) as vectors for anti-tumour ligand delivery,
such as tumour necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL), has emerged as one
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of the avenues of cytotherapy in cancer treatment, as these cells were shown to home the tumour
site and deliver targeted therapies. Furthermore, with the use of small molecular inhibitors in CSCs
and tumours to enhance the sensitivity of these cells to TRAIL or MSC-TRAIL mediated inhibition,
better treatment efficacy can be achieved. This review will first look into the characteristics of MSCs,
its effect on tumour tropism, the tumour-directed homing of MSCs, and the anti-cancer properties of
engineered MSCs that have been reported. The review will further focus on TRAIL in the treatment of
cancers, the idea of cancer stem cells, resistance of tumour and CSCs to TRAIL, sensitisation of CSCs,
and tumour to TRAIL-mediated inhibition, and the use of MSCs expressing TRAIL or MSC-TRAIL to
target sensitised CSCs and tumours.
2. Mesenchymal Stem Cells
The multipotent characteristic of human mesenchymal stem cells (MSCs) is an exclusive feature,
which is not seen in any other mature cells [5]. MSCs can be isolated from various sources, such as bone
marrow [6], umbilical cord blood [7], and adipose tissue [8], and can be cultured and stably expanded
for several passages while retaining its characteristics [9]. Compared to other potential cytotherapy,
MSCs are relatively non-immunogenic, thus overcoming the difficulties of immune rejection caused
by transplanted cells [10]. These characteristics make MSCs an attractive candidate for cell-based
therapy for degenerative diseases [11]. MSCs also express specific surface markers, such as (cluster
of differentiation) CD73, CD90, and CD105, while lacking other markers, such as CD34, CD45, major
histocompatibility complex (MHC) II, and hematopoietic stem cell markers [12]. Another unique
characteristic of MSCs compared to other adult stem cells, lies in the capacity of these cells to avoid
an immune response, because of the lack of MHC II and its co-stimulatory molecules (CD86 and
CD40), thereby reducing the risk of graft versus host rejection [13–15]. Accordingly, MSCs are great
candidates for bio-banking and autologous transplants [16]. These cells are also malleable to genetic
engineering, and have been shown to have the capacity to robustly express exogenous proteins [17].
These qualities have paved the way to use MSCs not just for the treatment of degenerative diseases,
but as cytotherapeutic-based vector for the treatment of various tumours.
3. MSCs and Its Effects in Tumour Tropism
The enhancement of the proliferative, resistance, and aggressive phenotypes of tumour cells
has been the subject of intense investigation. Most studies propose that the phenotypes are solely
acquired through genomic instability and abnormal cellular changes within the tumour cells [18],
while others view these characteristics as a process activated through the paracrine factors released
by the tumour microenvironment (TME) [19–21]. It has been shown that MSCs secrete microvesicles
and exosomes containing an array of cytokines, chemokines, and growth factors that regulate cellular
growth, angiogenesis, and inflammation [22,23]. As MSCs are also part of the stromal cells that reside
within the TME, it is expected that MSCs may contribute either to the development or inhibition
of a tumour. MSCs are also known to affect the proliferation and differentiation of dendritic cells,
macrophages, B and T cells, natural killer cells (NK cells), and mast cells [24].
Although a number of studies have shown that native MSCs are capable of inducing tumour
suppression and apoptosis, as seen in hepatoma [25], leukemia [26], and Kaposi’s Sarcoma [27], others
have demonstrated an opposite effect [28–30]. A recent study has proposed that therapy-educated
MSCs can enhance the resistant characteristic of pancreatic adenocarcinoma to therapy by enriching
CSCs [31]. The ambiguous role of MSCs during tumour development is attributed to the heterogenic
characteristics of MSCs that are the product of the MSC origin and growth conditions [32,33]. Indeed,
it is difficult to define the complex role of MSCs, as most studies were performed using MSCs from
different sources with varying conditions [34]. Despite the numerous studies that have advanced our
understanding of the biology of MSCs, leading to their subsequent applications in cancer therapy, more
studies are needed to fully understand MSCs’ influence on various tumour types. Figure 1 summarizes
the inhibitory and supportive effects of MSCs and the molecules that play a role in the process.
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Figure 1. Engineered mesenchymal stem cells (MSCs) act to support and inhibit tumour growth. 
MSCs could induce apoptosis in some tumours, while others have reported that MSCs might also 
inhibit apoptosis. MSCs could promote vascularization in the tumour microenvironment by 
secreting growth factors and might also lead to tumour inhibition by inducing cyclin dependent 
kinases (CDKs) and cyclins block that leads to cell cycle arrest. These ambiguous roles of MSCs 
suggested that more studies are needed to elucidate the exact function of MSCs in different tumour 
models for a safer treatment outcome. TRAIL—tumour necrosis factor-related apoptosis inducing 
ligand; VEGF—vascular endothelial growth factor; PDGF—platelet-derived growth factor; 
FGF—fibroblast growth factors; IFN—interferon; IGF—insulin-like growth factor; 
TGF—transforming growth factor; IDO—indoleamine 2,3-dioxygenase; HGF—hepatocyte growth 
factor; EGF—epidermal growth factor; PDGF—platelet-derived growth factor; 
WNT—proto-oncogene protein; IL—interleukin; SDF—stromal derived factor one alpha; 
AKT—serine/threonine kinase; PTEN—phosphatase and tensin homolog. 
  
Figure 1. Engineered mesenchymal stem cells (MSCs) act to support and inhibit tumour growth.
MSCs could induce apoptosis in some tumours, while others have reported that MSCs might also
inhibit apoptosis. MSCs could promote vascularization in the tumour icroenvironment by secreting
growth factors and might also lead to tumour inhibition by inducing cyclin dependent kinases
(CDKs) and cycli s block that leads to cell cycle arrest. These ambiguous roles of MSCs suggested
that more studies are needed to elucidate the exact function of MSCs in different tumour models
f r a afer tre tment outcome. TRAIL—tumour necrosis factor-related apoptosis inducing liga d;
VEGF—vascular endothelial growth factor; PDGF—platelet-derived growth factor; FGF—fibroblast
growth factor ; IFN—in erferon; IGF—insulin-lik growth factor; TGF—transforming growth factor;
IDO—indolea e 2,3-dioxygenase; HGF—hepatocyt growth factor; EGF—epiderm l growth fac or;
PDGF—platelet-derived growth factor; WNT—proto-oncogene protein; IL—interleukin; SDF—stromal
derived factor one alpha; AKT—serine/threonine kinase; PTEN—phosphatase and tensin homolog.
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4. Tumour Homing Capacity of Mesenchymal Stem Cells (MSCs)
The ability of the transplanted MSCs to home the tumour microenvironment has expanded the
therapeutic benefits of these cells beyond their use in degenerative diseases [35]. Numerous reports
have shown that MSCs are capable of infiltrating into the tumour stroma and its microenvironment,
and possibly contributing towards stromal support [36]. However, the definitive role of MSCs within
the tumour stroma is unknown. The exact mechanism in which MSCs migrate into the tumour
microenvironment is not fully understood. However, it is widely accepted that the secretion of
chemokines and cytokines from the tumour microenvironment and the expression of conjugate
receptors on MSCs are possible causes. Although the identities of the cytokines and chemokines,
as well as their respective receptors, are not yet known, it is postulated that a combination of several
receptors and ligands contributes to the homing characteristic.
One specific ligand, chemokine (C-X-C motif) ligand 12 (CXCL12), secreted by the tumours,
with its concomitant receptor (C-X-C chemokine) receptor type 4 (CXCR4), which is expressed mostly
in MSCs, has drawn particular interest, given its connection to the tumour-homing characteristic
of MSCs as well as its contribution to MSCs’ migration [37,38]. Some studies have suggested that
both CXCL12 and CXCR4 contributed significantly during angiogenesis and hematopoietic stem cell
mobilization, while others have suggested its major contribution during tumour development [39,40].
Although several studies have shown a strong connection between CXCL12/CXCR4 signalling towards
MSCs migration and the tumour homing capacity, the knockdown of these receptors does not inhibit
the homing potential of MSCs [41]. This may be due to the fact that some MSCs do not express the
receptor at all, and CXCL12/CXCR4 may not be the only molecules that influence the MSC migration.
Several studies have also suggested the ability of MSCs to home in on injured and inflamed tissues,
such as in cases of acute lung injury [42] and the liver cirrhotic model [43], indicating MSCs’ paracrine
and direct effects on regulating and healing of the damaged tissue.
5. Engineered MSCs for Anti-Tumour Therapy
5.1. Delivery of Anti-Tumour Cytokines
MSCs derived from the bone marrow, adipose tissue, and umbilical cord have been used as a
delivery vehicle for targeted anti-tumour therapies [44]. These immunoprivileged cells, in addition
to their reduced rejection risk, can home in on the tumour microenvironment, thus enhancing their
potential for use in allogeneic transplantation and cytotherapeutics [45–49]. Several studies that
altered the genes of these cells demonstrated that the exogenous expression of therapeutic genes,
such as bone morphogenic protein 2 (BMP-2), B-cell lymphoma 2 (BCL-2), and erythropoietin (EPO)
has enhanced the treatment efficacy of MSCs at the target site [50–52]. This leads to the idea of
using genetically-engineered MSCs as a vehicle to deliver biological anti-tumour agents directly at
the tumour microenvironment [45,53]. Many studies have shown that MSCs engineered to express
anti-tumour cytokines, such as interleukin-2 (IL-2) [54], interferon-beta (IFN-β) [55], TRAIL [45,46,48],
and IL-15 [56], are able to deliver these ligands directly to the tumour site and to efficiently induce
tumour regression. Moreover, the use of non-viral gene-delivery techniques has also been studied in
MSCs, suggesting an effective and yet safer method for gene-delivery to MSCs [57]. A previous work
using transfected MSCs derived from adipose tissue has shown that when these cells express a potent
anti-tumour agent called TRAIL, the engineered adult stem cells (termed MSC-TRAIL) are capable of
inducing apoptosis in glioblastoma (LN18) and hepatocellular carcinoma (HepG2) cells in vitro [58].
5.2. Delivery of Pro-Drug Converting Enzymes
Preclinical studies have shown that engineered MSCs expressing pro-drug converting enzymes
are useful for the treatment of late stage tumours and for the prevention of metastasis [59]. With this
strategy, the off-site accumulation of the active drug can be prevented, thus reducing the treatment
toxicity. An example of a pro-drug converting system is the yeast cytosine deaminase/5-fluorocytosine
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(5-FC), which uses MSCs to locally deliver yeast cytosine deaminase (yCD) to the tumour site.
The conversion of 5-FC to 5-fluorouracil (5-FU) by yCD induces cytotoxic tumour regression in
several cancers [60,61]. Another example of an MSC-mediated pro-drug converting system is the
thymidine kinase/ganciclovir system and nitroreductase/CB1954 system. Both systems have been
extensively studied in several tumour models, with promising effects [62,63].
5.3. MSCs as Vectors for Oncolytic Viruses
In addition to the utilization of MSCs as vectors to deliver cytokines and pro-drug enzymes
into tumours, MSCs have also been studied as a vehicle to deliver oncolytic viruses to the tumour.
Oncolytic viruses are viruses that induce tumour regression by direct tumour cell oncolysis [64,65] and
the disruption of the tumour microenvironment [66]. Several reports have shown that the delivery of
these viruses by MSCs enhanced the oncolytic effects of the virus in several tumour models [67–70].
The delivery of these viruses led to the destruction of tumour cells, as the viruses replicate and spread
to the surrounding stroma, which further induces tumour regression. Among the viruses that have
been studied, three types of viruses, namely the adenovirus, the measles virus, and the herpes simplex
virus have been shown to have a highly significant impact on reducing tumour growth [71]. The MSCs
loaded with oncolytic viruses were effective in reducing tumour metastasis in several models, as seen
in lung cancer [72], glioma [73], and breast cancer [74]. The direct inhibition of tumour growth was
also observed in hepatocellular carcinoma, pancreatic cancer, brain tumour, and non-small cell lung
cancer (NSCLC), in both in vitro and in vivo studies.
5.4. Safety Profile of Engineered MSCs
A different approach to using engineered MSCs has highlighted different anti-tumour efficacies
and several safety concerns. As a result of the expression of the TRAIL receptors (DR4 and DR5), which
are highly expressed in tumours, compared to normal cells, the efficacy of TRAIL to induce tumour
regression is higher, and the toxicity effect of TRAIL on normal cells is lower, compared with other
cytokines [75]. Engineered MSCs expressing pro-drug converting enzymes may enhance the effects
of chemotherapy by localized drug activation. However, if factors such as the number of migrated
MSCs to the tumour and the level of enzymes at the target site are not fully optimised, these factors
may hamper the overall treatment outcome in patients [76]. Although oncolytic viruses have emerged
recently as a potential agent in cancer treatment, the efficacy and safety of using this approach for
cancer treatment have been hindered because of the low virus spread at the tumour surrounding [77]
and the probability of these viruses reverting to their wild type, thus infecting the normal cells [78].
This approach of using MSCs as a vehicle for the delivery of anti-tumour agents and its safety are
summarized in Table 1.
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Table 1. Biological agents utilizing engineered mesenchymal stem cells (MSCs) as vehicle for ligand delivery and its safety. TRAIL—tumour necrosis factor-related
apoptosis inducing ligand; CSCs—cancer stem cells; IFN— interferon; IL—interleukin.
Biological Agents Mechanism Tumour Model Toxicity and Safety Concern References
IL-2
Reduce and inhibit tumour growth
dependent of natural killer (NK)
cells
Renal cell carcinoma, glioma May cause capillary leak syndromeand fluid accumulation [53,54,79]
IL-12 Inhibit tumour growth dependentof NK cells
Melanoma model, renal cell
carcinoma
Haematological toxicity, such as
neutropenia and thrombocytopenia [80–82]
IL-15 Abolished tumour growthdependent of NK and CD8+ T cells Pancreatic tumour Probability for autoimmune toxicity [56,83]
IL-18 Suppress proliferation, migration,and invasion Breast tumour
Haematological toxicity,
hypotension, and bradycardia [84,85]
IFN-β Inhibit tumour growth andmetastasis in vivo Melanoma, breast tumour
Haematological-, autoimmune-,
and hepato-toxicity [44,55,86]
TRAIL Induce apoptosis, inhibitclonogenicity and tumour bulk




(e.g., nausea, fever, and
constipation) and anaemia
[45,47,48,58,87]
Pro-drug converting enzymes Inhibition of tumour growthin vitro and in vivo
Glioma, prostate cancer,
osteosarcoma
“Off site” activated drug
accumulation [59–61,63]
Oncolytic virus Oncolytic viruses mediated tumourregression in vivo
Glioblastoma, brain metastasis,
leukemia and pancreatic cancer
Potential for virus mutation,
normal cell toxicity, and human
viral transmission
[71,78,88,89]
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6. Tumour Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) and Cancer Treatment
6.1. Tumour Necrosis Factor (TNF)-Related Apoptosis Inducing Ligand (TRAIL)
The tumour necrosis factor related apoptosis inducing ligand (TRAIL), also known as Apo2L, is
one of several members of the TNF gene superfamily that induces apoptosis. Its mechanism of action
is by activating the extrinsic apoptosis pathways through binding its two specific agonistic receptors
(TRAIL-R1/DR4 and TRAIL-R2/DR5) and three antagonistic decoy receptors [TRAIL-R3/DcR1,
TRAIL-R4/DcR2, and osteoprotegerin (OPG)] [90]. The TRAIL protein can either be a soluble ligand
or attached as a transmembrane protein by a hydrophobic amino acid bond. TRAIL is expressed
in a variety of normal tissues, such as the placenta, kidney, and spleen, and is secreted into the
peripheral blood because of the inflammatory response [91], viral infections [92], and malignant
diseases [93]. Several studies have documented the efficacy of TRAIL as a potent anti tumour agent on
its own [94–96], while others have recommended TRAIL as a combination treatment because of the
possible resistance in some tumour models [97–99]. These studies are detailed and elaborated in the
next sections.
6.2. TRAIL Treatment in Solid Tumours
Several studies have documented the efficacy of TRAIL in inhibiting the proliferation and inducing
apoptosis in vitro, in a variety of tumours, including colorectal cancer [100], glioblastoma [101],
and NSCLC [102]. Furthermore, TRAIL has also been reported to inhibit the proliferation of several
chemoresistant cancer cell lines [103,104]. In small animal models, TRAIL-induced tumour regression
was well documented in colon and breast carcinoma of SCID mice [105,106]. However, some have
described the poor bioavailability and short half-life of TRAIL upon administration to a xenograft
model, which eventually resulted in poor bioavailability of the ligand [105]. Nonetheless, modifications
of the TRAIL protein structure and fusion with other immunoglobulin molecules have significantly
prolonged its half-life and perhaps even enhanced its anti-tumour activity [107].
6.3. Synergistic Effects of TRAIL-Based Combination Therapy
The pre-treatment of tumour cells by small molecule inhibitors have been shown to increase
the sensitivity of TRAIL-induced apoptosis [108]. These molecules include the inhibitors of
mammalian target of rapamycin (mTOR) [109], proteasome [110], histone deacetylases (HDAC) [111],
and BCL-2 [112], and they have been used in combination with recombinant TRAIL to inhibit
specific signalling molecules that would interfere with the extrinsic activation of apoptosis by TRAIL.
In lung cancer, compounds such as bortezomib [102], cardiac glycosides [113], and transhinone
IIA [114] have been reported to have synergistic or sensitising effects on TRAIL-mediated apoptosis.
The pre-treatment of tumour cells by standard chemotherapy drugs have also been shown to be a
promising approach, based on several in vitro studies [97,99,115]. However, all of these approaches,
which often target non-CSCs, may not be able to eradicate the tumour completely. Strategies to target
TRAIL-resistant CSC populations should be explored for better treatment efficacy.
7. The Existence of Cancer Stem Cells
Tumours are composed of heterogeneous populations of cells. Each sub-population varies in its
differentiation, proliferation, and tumourigenic capacity [116,117]. In vivo models have demonstrated
that a small sub-population of cells has strong stem cell or pluripotent characteristics [118]. They are
known as cancer stem cells (CSCs), or cancer initiating cells, and are able to initiate tumour
development in vivo [119]. Classical chemotherapy may reduce the bulk of the tumour and improve
the patient’s quality of life, but because of the strong chemoresistant characteristic of CSCs from high
aldehyde dehydrogenase (ALDH) enzyme activity, enhanced DNA repair mechanism, and the efflux
of drugs by the adenosine triphosphate (ATP)-binding cassette or ATP-binding cassette transporters
(ABC) transporters, most patients that underwent chemotherapy eventually experienced relapse.
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Therefore, it is by identifying and therapeutically targeting these stem cells that the response and
outcome of treatments could be improved.
The cluster of differentiation (CD) molecules have been used as the most reliable technique for the
isolation and identification of cell populations enriched with stem cell properties. One such example
is CD133, which has recently been identified as the marker for CSC in lung cancer [120], prostate
cancer [121–123], brain cancer [124–127], colon cancer [128–130], and hepatic carcinoma [131–134].
CSCs are also identified as the side population (SP), based on the expression of the ABCG2 protein and
the ability to efflux Hoechst dye [135]. In a recent study, Lim and his group identified a combination of
CD166-positive and Lin-negative sub-population of lung cancer cells that link a glycine metabolism
enzyme to tumour formation as a novel therapy targeting a specific metabolic pathway in NSCLC [136].
In the identification of the CSCs derived from non-small cell lung cancer, markers such as the CD133,
SP population, and ALDH 1 have been extensively studied and reported [137–139]. We have recently
identified and characterised a novel double positive (CD166+/CD44+ and CD166+/EpCAM+) CSC
sub-population isolated from NSCLC cell lines (A549 and H2170), and showed that these two sub
populations exhibit a self-renewal capacity, higher mobility, resistance to apoptosis, and the ability to
differentiate towards the mesenchymal lineage [140]. A list of CSC markers and the type of tumours
are summarized in Table 2.
Table 2. CSCs markers from different tumour types. ALDH—aldehyde dehydrogenase; SP—side
population; ABCG2—ATP-binding cassette sub-family G member 2; CD—cluster of differentiation.
Cancer Type CSCs Markers References
Non-small cell lung cancer (NSCLC) ABCG2
+, CD133+, CD44+,
EpCAM+, CD166+, ALDH+ [137,138,140]
Breast CD44+/CD24−, ALDH+ [141,142]
Colon CD133+, EpCAM high/CD44+ [128,129,143,144]
Head and neck CD44+, SP, ALDH [145,146]
Prostate CD133+, CD44+, α2β1high [147,148]
Brain tumour/glioma CD133+, CD15+, CD90+, CD49f+ [126,149,150]
8. Resistance of CSCs to TRAIL and Apoptosis
CSCs are known for being highly resistant to apoptosis even through the stimulation of the
TRAIL death ligand. In general, the remarkably impaired regulation of apoptosis in CSCs compared to
non-CSCs are because of the lower expression of death signals (i.e., CASP8/caspase 8, CASP3/caspase
3, and PARP/Poly [adenosine diphosphate ribose (ADP-ribose)] polymerase 1) and the higher
expression of anti-apoptotic molecules (i.e., cFLIP/cellular FLICE-like inhibitory protein, BCL-2/B-cell
lymphoma 2, and XIAP/inhibitors of apoptosis), leading to the characteristics of CSCs’ being highly
resistant to apoptosis [151]. Other factors include the tumour microenvironment, genetics, epigenetics,
and inter- and intra-tumour heterogeneity, which may also contribute to the resistance. High
expressions of the DR4 and DR5 receptors, which are the agonistic TRAIL receptors, were reported as
the contributor of CSCs’ resistance to TRAIL-mediated effects and the chemo-resistant characteristic
observed in colon cancer [152]. However, in glioblastoma, the low expression of the death receptor
(DR4 and DR5) and high expression of cFLIP, a master anti-apoptotic regulator molecule, led to
the glioblastoma-derived CSCs resistance to TRAIL [153]. The activation of the extrinsic apoptotic
pathways through DR4 and DR5 ligand-activation promotes the expression of various apoptosis
inhibitory proteins in CSCs that include the NF-κB, which also makes CSCs resistant to TRAIL-based
therapy, as seen in glioblastoma [154]. Other anti-apoptotic signalling molecules, such as X-linked
inhibitor of apoptosis proteins (XIAPs), were also observed to reduce the effects of TRAIL-mediated
apoptosis in CSCs derived from nasopharyngeal carcinoma [155].
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9. Sensitisation of CSCs to TRAIL and Apoptosis
The ability of CSCs to evade apoptotic signals contributes towards chemoresistance in most
cancers. Therefore, therapeutic strategies that can enhance the onset of apoptosis in CSCs may
serve as a more promising approach. It is known that the high expression of anti-apoptotic genes
in CSCs makes these cells highly resistant to cell death and apoptosis, which contributes greatly to
cancer progression [136,156,157]. These anti-apoptotic genes present potential therapeutic targets,
particularly to discriminate CSCs from non-CSCs [158]. It has been shown that, by regulating specific
anti-apoptotic genes through gene knock down or silencing, the sensitivity of CSCs toward therapy
can be enhanced [4]. This means that combination therapies can sensitize CSCs against TRAIL,
and common chemotherapy might be an ideal approach for effective treatment.
Chemoresistance of tumour cells that contributes towards cancer recurrence is mostly comprised
of a pool of CSCs that are TRAIL-resistant. Owing to the high cFLIP expression in most tumours,
it is believed that the overexpression of cFLIP is also the main contributor to TRAIL-resistance in
CSCs [159–162]. One study demonstrated that by regulating this molecule, the sensitivity of tumours to
TRAIL-mediated apoptosis and to common chemotherapies, such as taxol, gemcitabine, and cisplatin,
is enhanced [153,163,164]. In breast cancer stem cells, the silencing of cFLIP by siRNA or a chemical
known as droxinostat [165], sensitised them to TRAIL-mediated effects, and the combination of
both the cFLIP inhibition and the TRAIL induction resulted in a significant reduction in the tumour
bulk, metastasis, and self-renewal of the breast CSCs. It was also shown that CD133-positive brain
cancer stem cells expressed a high level of BCL-2 upon TRAIL induction, and a knockdown of BCL-2
subsequently enhanced the sensitivity of the CSCs to TRAIL-mediated inhibition [166]. Moreover,
using second mitochondria-derived activator of caspases (SMAC) mimetics the induced inhibitor of
apoptosis (IAP) degradation in nasopharyngeal carcinoma, and the effects of the TRAIL-mediated
apoptosis was enhanced [155]. Finally, in colon cancer, the knockdown of Sirtuin 1 (SIR1) sensitised
the colon CSCs to TRAIL-induced cytotoxicity [167].
10. Enhancing the Effect of MSC-TRAIL by Tumour Sensitisation
Mesenchymal stem cells, with their unique ability to home in on the tumour microenvironment
and express exogenous transgenes, have garnered considerable interest as a viable therapeutic strategy.
Engineered MSCs expressing TRAIL were able to kill the side population cells in the squamous and
adenocarcinoma of the lung cancer cell lines, indicating the feasibility of these engineered cells to
selectively kill putative cancer stem cells [168]. Similarly, the MSC-TRAIL was observed to significantly
induce tumour cell death through caspase-mediated apoptosis in primary glioma-derived CD133
cells in vitro [169]. Moreover, the expression of TRAIL by MSCs enhanced the oncolytic effect of
Newcastle disease virus (NDV) in glioma stem cells, resulting in positive synergistic effects compared
to TRAIL or NDV alone [170]. In addition, the combination of MK886 (a lipoxygenase inhibitor)
and MSC-TRAIL was beneficial in inducing the apoptosis of malignant glioma tumour cells via the
upregulation of DR5, downregulation of anti-apoptotic protein survivin, and significant increase in the
caspases’ activity [171]. All of these studies demonstrate that the MSC-TRAIL can selectively target
CSCs, and further investigations to refine the approach for clinical applications are warranted.
Several reports have also suggested that, through the regulation of specific cellular signalling
and proteins, the efficacy of MSCs expressing TRAIL to inhibit metastasis in several cancers was
enhanced. For example, MSC-TRAIL has been shown to inhibit metastasis of the NSCLC derived-H460
cell line combined with Claudin-7, a small molecule that regulates mitogen-activated protein
kinases/extracellular signal-regulated kinases (MEK/ERK) signalling pathways [172]. In pancreatic
cancer, targeting of the XIAP [173] molecule resulted in the increased sensitivity to the MSC-TRAIL
treatment and the suppression of metastasis [174]. It was shown in a metastatic renal cell carcinoma
model that overexpressing thymidine kinase increased the sensitivity of the tumour cells to
dodecameric TRAIL secreted by MSCs, and suggested that the combined administration of MSC-TRAIL
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and thymidine kinase is a potent strategy for the long-term remission of metastatic renal cell
carcinoma [175].
The dual effects of common chemotherapies, either as a cytotoxic drug or sensitiser to MSC-TRAIL,
were recently described [176]. This was seen as a promising approach, especially to patients that
have exhausted all available treatments. Recently, low dose cisplatin was able to increase the
expression of TRAIL agonistic receptor DR4/5, and enhanced the efficacy of MSC-TRAIL, eventually
decreasing tumour growth in glioblastoma multiforme [177] and hepatocellular carcinoma animal
models [178]. A similar result was observed in a study using a mouse xenograft model of malignant
glioma, where the administration of temozolomide enhanced the tumour sensitivity to MSC-TRAIL,
by increasing the DR5 receptor expression and lowering the XIAPs and cFLIP expression [179].
Moreover, the sensitisation of human breast cancer cells by doxorubicin enhanced the apoptotic
effect of the MSC-TRAIL and synergistically reduced the tumour growth in the xenograft mouse
model [180]. A simplified diagram of the approach and the signalling involved upon TRAIL activation
by MSC-delivery is illustrated in Figure 2.
Challenges in MSC-TRAIL Applications: Discrepancies from In Vitro to In Vivo Models
The level of the TRAIL receptor expression does not correlate directly with the sensitivity of
the tumour to the TRAIL-induced apoptosis [181,182]. Moreover, the sensitisation of these resistant
tumour cells may yield a different effect towards TRAIL and MSC-TRAIL treatment in an in vitro
and in vivo model. For example, in TRAIL-resistant colorectal carcinoma cells (CRC), subapoptotic
genotoxic damage caused by 5-fluorouracil (5-FU) sensitised TRAIL-resistant CRC cells to MSC-TRAIL
mediated inhibition in vitro. However, the sensitising effect was not achieved in an in vivo CRC mouse
model. Rather, MSC-TRAIL seemed to support growth of the tumour, which invoked a cautionary
warning, should the MSC-TRAIL be used in the clinic [183]. This may be due to the low intratumoural
activity of 5-FU and sub-optimal tumour integration of MSC-TRAIL, which may hamper the overall
treatment outcome [184]. It is also suggested that choosing the right tumour model that allows long
term integration of the MSC-TRAIL to the target site is crucial for an effective in vivo model, as shown
in the TRAIL-resistant medulloblastoma model [185]. It is expected that, by targeting the specific
molecules that contributed to the TRAIL-resistant characteristics in these cells [186] and choosing a
xenograft models with the most effective MSC-TRAIL integration, such as a pulmonary disease [187]
or a metastatic model [188], a better treatment efficacy and tumour homing of MSC-TRAIL can
be achieved.
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Figure 2. Sensitisation of tumour or cancer stem cells (CSC) to MSC-TRAIL induced apoptosis.
An increase in the anti-apoptotic molecules (e.g., X-linked inhibitor of apoptosis proteins [XIAPs],
cellular FLICE-like inhibitory protein [cFLIP], and B-cell lymphoma 2 [BCL-2]) upon TRAIL
activation can be circumvented using specific inhibitors, as illustrated above. Through tumour
sensitisation by anti-apoptosis gene silencing or specific DR5 receptor enhancement, and the
utilization of MSCs as a vehicle for TRAIL delivery, a better treatment outcome could be achieved.
SMAC—second mitochondria-derived activator of caspases; FADD—fas-associated protein with death
domain; Cas—caspase; BID—BH3 interacting-domain death agonist; BAK—BCL-2 antagonist killer
1; BAX—BCL-2 associated X. Inhibitors: SAHA—suberoylanilide hydroxamic acid; shRNA—short
hairpin RNA; siRNA—small interfering RNA; RNAi—RNA interference. The arrow and t-bar represent
activated and inhibitory interactions respectively.
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11. Conclusions
Through an integrated approach, significant improvements have been made in the treatment of
cancer. It was shown that the existence of cancer stem cell populations contributes to the challenges
of developing an effective treatment in cancer. The regulation of specific molecules that lead to
chemotherapy resistance characteristics in tumour cells and CSCs’ may represent as an ideal approach
for a better treatment efficacy. Moreover, combining the tumour-homing capacity of MSCs and genetic
engineering of the cells to express TRAIL-ligand, will enable the specific targeting of CSCs, thus
paving the way towards a more effective treatment. However, several questions remain, such as the
exact mechanism of the MSCs’ tumour-homing capacity and the fate of the MSCs after transfusion.
These questions need to be answered to ensure the safety and efficacy of the treatment in future.
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